Indivior PLC (LON:INDV) had its price target lowered by equities research analysts at Jefferies Group LLC from GBX 540 ($6.97) to GBX 358 ($4.62) in a report released on Friday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s target price indicates a potential upside of 16.73% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on INDV. Citigroup Inc. reissued a “neutral” rating and issued a GBX 280 ($3.62) price target on shares of Indivior PLC in a research note on Tuesday. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 490 ($6.33) target price on shares of Indivior PLC in a research note on Wednesday, May 31st. Finally, Royal Bank Of Canada upgraded Indivior PLC to an “outperform” rating and lifted their price target for the company from GBX 390 ($5.04) to GBX 470 ($6.07) in a report on Friday, July 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of GBX 412.17 ($5.32).

Indivior PLC (LON INDV) traded up 1.22% during trading on Friday, hitting GBX 306.70. 2,849,164 shares of the stock were exchanged. Indivior PLC has a one year low of GBX 246.50 and a one year high of GBX 421.50. The company’s market cap is GBX 2.21 billion. The stock’s 50 day moving average is GBX 372.74 and its 200-day moving average is GBX 338.39.

Indivior PLC (LON:INDV) last issued its quarterly earnings data on Wednesday, July 26th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.14. On average, equities research analysts expect that Indivior PLC will post $0.37 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Indivior PLC (INDV) Given New GBX 358 Price Target at Jefferies Group LLC” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/09/indivior-plc-indv-given-new-gbx-358-price-target-at-jefferies-group-llc.html.

About Indivior PLC

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.